Gene-based fungal infection prevention in leukemia patients

This trial is testing a new approach to preventing dangerous fungal infections in people with acute myeloid leukemia undergoing chemotherapy. Instead of giving everyone the same strong antifungal medication, researchers will use a genetic test to identify which patients are at highest risk for these infections—and only those patients will receive posaconazole, a broad-spectrum antifungal drug. The goal is to give the right treatment to the right patients while avoiding unnecessary medication for those at lower risk.

Fungal infections are a serious complication of leukemia treatment that can be life-threatening, but not all patients are equally at risk. Currently, doctors often prescribe expensive, broad-spectrum antifungal medication to everyone as a precaution. This trial exists to find a smarter way: by using genetics to predict who really needs this strong medication, doctors can prevent infections more effectively while reducing unnecessary treatment and its side effects.